DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
At the Company’s Annual Meeting of Stockholders on June21, 2018 (the “Annual Meeting”), the following actions were taken. The proposals below are described in detail in the Company’s definitive proxy statement dated April26, 2018 for the Annual Meeting.
Proposal 1
The nominees for election as directors, each for a one-year term, were elected based upon the following votes:
|
Nominee |
For | Against | Abstain | Broker Non-Votes |
|
Douglas M. Fambrough, III, Ph.D. |
41,533,073 | 33,128 | 4,700 | 5,398,882 |
|
Martin Freed, M.D. |
41,415,019 | 151,132 | 4,750 | 5,398,882 |
|
Brian K. Halak, Ph.D. |
41,500,068 | 66,083 | 4,750 | 5,398,882 |
|
Stephen J. Hoffman, M.D., Ph.D. |
41,180,573 | 384,738 | 5,590 | 5,398,882 |
|
Peter Kolchinsky, Ph.D. |
41,458,149 | 108,052 | 4,700 | 5,398,882 |
|
Adam M. Koppel, M.D., Ph.D. |
41,497,573 | 65,578 | 7,750 | 5,398,882 |
|
Dennis H. Langer, M.D., J.D. |
41,425,629 | 137,572 | 7,700 | 5,398,882 |
|
David M. Madden |
41,457,744 | 106,457 | 6,700 | 5,398,882 |
Proposal 2
The proposal to ratify the appointment of Deloitte& Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018 was approved based upon the following votes:
|
For |
Against |
Abstain |
Broker Non-Votes |
| 46,898,505 | 71,278 | — | — |
About DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).